The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
On March 17, the National Comprehensive Cancer Network (NCCN) updated its 2026 Clinical Practice Guidelines to include ANKTIVA in combination with BCG for treating patients with BCG-unresponsive non-muscle invasive bladder cancer. On March 24, ImmunityBio's shares fell by 20% after the U.S. Food and Drug Administration issued a warning letter regarding a television advertisement and podcast promoting its cancer therapy, which were deemed false or misleading and in violation of federal law.